Laser and immunotherapy combo takes on deadly brain tumors
NCT ID NCT03277638
First seen Jan 11, 2026 · Last updated May 02, 2026 · Updated 16 times
Summary
This study tests a new approach for adults with recurrent glioblastoma, an aggressive brain cancer. It combines a minimally invasive laser that heats and destroys tumor tissue (LITT) with pembrolizumab, an immunotherapy drug that helps the immune system fight cancer. The goal is to see if this combination is safe and improves tumor shrinkage and survival compared to standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, 44106, United States
Conditions
Explore the condition pages connected to this study.